Sujatha Addagatla, MD
Nephrology · Niagara Falls, NYNPI 1720168198
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.9%), speaking fees and education — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Amgen at 44.9% of the total. Reporting peaked in 2024 at $321 and has fallen 90.4% since, to $31 in 2025. That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.
Across 55 payments — averaging $12.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$313
- Vifor Pharma, Inc.$200
- Travere Therapeutics, Inc.$184
What the payments were for
- Speaking & faculty fees$20029%
- Food & beverage$31345%
- Education$18426%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 8 | $313 |
| Vifor Pharma, Inc. | 1 | $200 |
| Travere Therapeutics, Inc. | 46 | $184 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$698 in reported general payments places this provider in the 50th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 95 | $16,399 |
| Bumetanide | 330 | $11,020 |
| Sevelamer Carbonate | 40 | $8,202 |
| Calcium Acetate | 95 | $7,624 |
| Hydralazine Hcl | 232 | $3,869 |
| Amlodipine Besylate | 488 | $3,196 |
| SpsSodium Polystyrene Sulfon/Sorb | 12 | $1,455 |
| Potassium Chloride | 21 | $1,156 |
| Sodium Polystyrene Sulfonate | 17 | $1,144 |
| Midodrine Hcl | 48 | $1,128 |
| Cinacalcet Hcl | 15 | $1,123 |
| Metolazone | 57 | $997 |
| Spironolactone | 74 | $770 |
| Hydrochlorothiazide | 150 | $615 |
| Metoprolol Succinate | 36 | $541 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Niagara Falls
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
- Jai RadhakrishnanNew York$369K
- Savneek ChughHawthorne$325K
- Gerard TepedinoManhasset$308K
- Frank CortazarAlbany$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.